Shots:

• The P-II/II DIAN-TU-001 study involve assessing of Roche’s gantenerumab and Eli Lilly’s solanezumab vs PBO in 194 patients with ADAD for up to 7yrs. across 24 sites including the US- Australia- Canada- France- Spain & the UK
• The study resulted in not meeting its 1EPs i.e- did not slow the rate of cognitive decline in patients assessed by DIAN multivariate cognitive endpoint and demonstrated consistent safety profile with other clinical studies of the therapy along with no new safety issues
•  Gantenerumab is an investigational therapy targeting aggregated forms of beta-amyloid and removes beta-amyloid plaques- currently being evaluated in two P-III studies GRADUATE 1 and 2- assessing gantenerumab in 2-000+ patients with sporadic AD across 30 countries globally

Click here ­to­ read full press release/ article 

Ref: Roche | Image:  Roche